Valuation: Axsome Therapeutics, Inc.

Market Cap 12.11B 10.56B 9.74B 8.94B 17B 1,165B 17.28B 116B 45.57B 569B 45.46B 44.46B 1,962B P/E 2026 *
-115x
P/E 2027 * 42.4x
Enterprise Value 12B 10.46B 9.66B 8.86B 16.84B 1,155B 17.12B 115B 45.15B 564B 45.04B 44.05B 1,944B EV / Sales 2026 *
12.3x
EV / Sales 2027 * 7.34x
Free-Float
84.36%
Yield 2026 *
-
Yield 2027 * -
1 day+0.96%
1 week-4.90%
Current month-2.96%
1 month-6.91%
3 months+28.97%
6 months+34.19%
Current year+30.05%
1 week 224.7
Extreme 224.7001
249.55
1 month 224.7
Extreme 224.7001
260.19
Current year 152.28
Extreme 152.28
260.19
1 year 96.09
Extreme 96.09
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 19.38
Extreme 19.38
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 2012-01-11
Director of Finance/CFO 51 2018-05-15
Chief Operating Officer 42 2014-03-31
Director TitleAgeSince
Chairman 57 2012-01-11
Director/Board Member 64 2014-11-30
Director/Board Member 58 2014-11-30
Date Insider Type Main position Quantity % Market Cap.
Jun. 30Fiscal year

Chief Executive Officer

148,998 0.2895%
Jun. 10Sell

Director

-286 0.0006%
Jun. 09Sell

Director

-300 0.0006%
Change 5-day change 1-year change 3-year change Capi.($)
+0.96%-4.90%+111.46%+222.60% 12.11B
+1.27%-1.74%+16.45%-7.53% 66.75B
+1.38%-7.13%+36.60%+197.15% 50.65B
+1.10%+38.30%+38.30%+38.30% 42.55B
-0.98%-1.79%-49.61%-53.35% 41.15B
+2.76%-4.11%+48.18%-29.29% 28.34B
+1.25%-14.40%+107.73%-43.73% 26.76B
+0.18%-2.51%+64.46%+86.35% 22.95B
+7.77%+11.30%+18.35%+199.08% 20B
-1.70%+6.10%+73.33%+353.68% 16.48B
Average +0.84%-2.72%+46.52%+96.33% 32.77B
Weighted average by Cap. +0.79%-3.08%+34.15%+65.31%

Financials

2026 *2027 *
Net sales 979M 854M 788M 723M 1.37B 94.22B 1.4B 9.38B 3.68B 46.02B 3.68B 3.6B 159B 1.59B 1.39B 1.28B 1.18B 2.24B 153B 2.28B 15.29B 6B 74.98B 5.99B 5.86B 259B
Net income -107M -93.63M -86.42M -79.29M -151M -10.33B -153M -1.03B -404M -5.05B -403M -394M -17.4B 310M 270M 250M 229M 435M 29.84B 443M 2.97B 1.17B 14.58B 1.16B 1.14B 50.26B
Net Debt -111M -96.54M -89.1M -81.75M -155M -10.65B -158M -1.06B -417M -5.2B -416M -407M -17.94B -394M -343M -317M -291M -553M -37.9B -562M -3.77B -1.48B -18.51B -1.48B -1.45B -63.83B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,220
Date Price Change Volume
26-07-15 $237.53 +0.96% 701,057
26-07-14 $235.26 +3.06% 482,756
26-07-13 $228.28 -2.36% 843,010
26-07-10 $233.80 -6.09% 804,667
26-07-09 $248.95 +1.38% 621,739
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
235.26USD
Average target price
280.39USD
Spread / Average Target
+19.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock